Ticagrelor China Pharmacokinetic/Pharmacodynamic Study
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
open label, single centre, randomised, Phase IV, pharmacokinetic, pharmacodynamic, and safety
study to evaluate single and multiple doses of 45, 60, and 90 mg of ticagrelor in Chinese
patients with stable coronary heart disease